AMZN: EXPANDED COLLABORATION AMZN: INTEL PARTNERSHIPPG: LEAST SHORTED STOCKBA: UNEXPECTED CASH OUTFLOWTGT: PEAK SEASON DSV: MODELLING CAPITAL APPRECIATIONAMZN: MESSAGE FROM CEODSV: CONSENSUS ESTIMATES RXO: COYOTE DEAL CLOSEDDHL: POSTE PARTNERSHIPDSV: SCHENKER BOOST DAY THREEAAPL: PRESSURE BUILDS WMT: ANOTHER RECORDFWRD: ON THE RISEBA: NEW LOWWTC: NEW DAY NEW HIGH DSV: SCHENKER BOOST DAY TWO
AMZN: EXPANDED COLLABORATION AMZN: INTEL PARTNERSHIPPG: LEAST SHORTED STOCKBA: UNEXPECTED CASH OUTFLOWTGT: PEAK SEASON DSV: MODELLING CAPITAL APPRECIATIONAMZN: MESSAGE FROM CEODSV: CONSENSUS ESTIMATES RXO: COYOTE DEAL CLOSEDDHL: POSTE PARTNERSHIPDSV: SCHENKER BOOST DAY THREEAAPL: PRESSURE BUILDS WMT: ANOTHER RECORDFWRD: ON THE RISEBA: NEW LOWWTC: NEW DAY NEW HIGH DSV: SCHENKER BOOST DAY TWO
LCP Consulting senior director Julian Mosquera blogs on why pharmaceutical supply chains have to change: the short answer is that with a set of blockbusters coming off patent in the next five years, the era of high margins on drugs is coming to an end and producers now recognise that maintaining profits means a new focus on costs.
